Suggested remit: To appraise the clinical and cost effectiveness of pertuzumab within its marketing authorisation for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2) positive breast cancer.
Status In progress
Process STA pre-2018
ID number 1192

Provisional Schedule

Committee meeting: 3 16 October 2018
Expected publication 09 January 2019

Project Team

Project lead Thomas Feist

Email enquiries


Companies sponsors Roche
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Breast Cancer Care
  Breast Cancer Now
  UK Breast Cancer Group
Professional groups Association of Breast Surgery
  Association of Cancer Physicians
  British Association of Surgical Oncology
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  UK Clinical Pharmacy Association


General commentators All Wales Therapeutics and Toxicology Centre
  Department of Health and Social Services and Public Safety, Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Cancer Research Institute


Key events during the development of the guidance:

Date Update
17 August 2018 - 07 September 2018 Appraisal consultation: 2
19 July 2018 Committee meeting: 2
15 June 2018 - 06 July 2018 Appraisal consultation: 1
22 May 2018 Committee meeting: 1
01 December 2017 Invitation to participate
21 June 2017 - 18 July 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
22 July 2016 Referral
22 July 2016 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance